EVALUATION OF A MODIFIED BIOMATERIAL OF TYMPANOTONUS FUSCATA SHELL POWDER II: FORMULATION OF PYRIMETHAMINE AND PYRIDOXINE HYDROCHLORIDE TABLETS
A novel modified biomaterial of periwinkle shell powder, MBPSP was developed from Tympanotonus fuscata. It was assessed as a bulking agent in the formulation of pyrimethamine and pyridoxine hydrochloride tablets adopting dicalcium phosphate dihydrate (DCP) as a standard. A 100 g of the ground periwinkle shell was broken down in 166.0 ml of 2 M hydrochloric acid, clarified and treated with 5 M sodium hydroxide. The thick white precipitate obtained was washed severally and to it, ortho-phosphoric acid was dropped in bits until a thick, dehydrated bulk was attained which was dried at 60 o C and classified with 250 Î¼m sieve. The product was coded MBPSP. Two batches of granules containing pyrimethamine (25 mg) and pyridoxine hydrochloride (50 mg) were generated by the wet granulation employing MBPSP alongside DCP. The granules were lubricated with magnesium stearate and talc and compacted into tablets at 7.55kN using a 10.50 mm diameter die and flat-faced punch fixed in a hydraulic hand press. The tablet produced were evaluated using the British Pharmacopoeia specifications. The weight variation for the pyrimethamine or pyridoxine hydrochloride tablets containing MBPSP or DCP were 0.06, 0.1, 0.097 and 0.143 % respectively. The total drug content for the individual lots of tablets for either pyrimethamine or pyridoxine hydrochloride was within 85.00-115.00 % of their label claim. Higher mechanical strength were noted for the batch of tablets manufactured with DCP and containing pyrimethamine and pyridoxine hydrochloride than MBPSP. Though the entire batches of tablets for the two drugs manufactured with either MBPSP or DCP disintegrated in less than 5.00 min with no significant difference in their individual disintegrating time (p>0.05), pyridoxine hydrochloride tablets prepared with DCP disintegrated in lesser time when compared to MBPSP (p<0.05). Only the pyrimethamine tablets prepared with MBPSP attained 75.00 % drug release in 45.00 min in line with the United States Pharmacopoeia (USP) criteria. Therefore, MBPSP could be another very useful bulking agent in the formulation of pyrimethamine immediate-release tablets by the wet granulation technique.
Keywords: Modified biomaterial, Tympanotonus fuscata, periwinkle, shell, pyrimethamine, pyridoxine hydrochloride, tablet.
2. Avachat A and Ahire V. Characterization and evaluation of spray dried co- processed excipients and their application in solid dosage forms. Indian J Pharm Sci, 2007; 69:85-90.
3. Liebermam H.A. and Lachman L. â€˜â€˜Tabletsâ€™â€™: in Pharmaceutical Dosage Forms, Vol.1, Marcel Dekker Inc.; New York, 1980.
4. Carr, R.L. â€˜â€˜Evaluating flow properties of solidsâ€™â€™, Chem. Eng., 1965; 72:163 â€“ 168.
5. Lachman L.; Lieberman H.A. & Kanig J.L. â€˜â€˜Sustained Release Formulationsâ€™â€™, in: Theory and Practice of Industrial Pharmacy, 3rd ed.; Lea and Febiger, Philadelphia, 1986.
6. WHO. Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines. 15-19 October 2007. Available from: http://studylib.net/doc/9264523/guidelines---world-health-organization. Retrieved on 22nd June 2017.
7. Wade A, Weller PJ. Handbook of Pharmaceutical Excipients. 11th Ed. The Pharmaceutical Press: London, 1994; 426-8.
8. Edmund J. â€œSea shells & other mollusc found on West African shores & estuariesâ€. In: Descriptive manual of Janet Edmund. Ghana University press, Accra, 1978; 20:100-101.
9. Ugoeze K.C, Chukwu A. Preliminary Evaluation of the Properties of Biomaterial of Tympanotonus fuscata shell as Pharmaceutical Excipient. Int. Res. J. Pharm. 2015; 6(2):104-107.
10. Ugoeze K.C, Chukwu A. Physico-chemical Properties of a Modified Biomaterial from Tympanotonus Fuscata (Periwinkle) Shell Powder Considered as Pharmaceutical Excipient. Journal of Pharmaceutical and Allied Sciences, 2017; 14(1):2417-2429.
11. Ugoeze K. C., Udeala O. K. Application of Periwinkle Shell Bio-ash (Ugoeze-bio-ash) as CO2 Donor in the Formulation of an Effervescent Low Dose Aspirin Tablet. American Journal of Biomedical Science and Engineering, 2015; 1(5): 63-70.
12. British Pharmacopeia, Her Majestyâ€™s Stationery Office, London, 1998.
13. Shangraw R.F. Direct Compression Tabletting, Encyclopaedia of Pharmaceutical Technology, Vol.4, Marcel Dekker, U.S.A., 2nd ed., 1988; pp. 85-160.
14. Shangraw R.F. Compressed tablets by direct compression granulation in: Pharmaceutical Dosage Forms: Tablets, Vol.1, Marcel Dekker, U.S.A., 2nd ed., 1989; p. 195-246.
15. Setn B.B; Bandelin F.J. and Shangraw, R.F. Tablets in: Pharmaceutical Dosage Forms, Vol. I; Liebermann, H. and Lachman, L. (eds.), Marcel Dekker Inc, New York, 1980; p.110.
16. Marks A.M. & Sciarra J.J. Effects of size and other physical properties of granules and their corresponding tablets, J. Pharm. Sci. 1968; 57: 497.
17. Parrot, E.L. Pharmaceutical Technology; Fundamental Pharmaceutics, Burges Pub. Co., Minneapolis, 1970; pp. 17-18, 74.
18. Lazarus J. and Lachman L. Experiences in development of directly compressible tablets containing potassium chloride, J. Pharm. Sci. 1966; 55:1121.
19. Rasenack N. and Muller B.W. Crystal habit and tableting behaviour, Int. J. Pharm. 2002; 244:45-57.
20. Sherringtonn P.J.; Oliver R. Granulation: in: Encyclopaedia of Pharmaceutical Technology, Vol. 3, 2nd Edition, Edited by James Swarbrick and James C. Boylan, Marcel Dekker, Inc. New York, 1981; pp. 2713-2731.
21. Ejiofor O; Esezobo S, Pilpel N. The plasto-elasticity and compressibility of coated powders and the tensile strength of their tablets, J. Pharm. Pharmac. 1986; 38(1):1-7.
22. The United States Pharmacopoeia, U.S.P, NF. The United States Pharmacopoeial Convention, Rockville, 2007.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).